Blueprint Medicines Corporation (BPMC) has a consensus analyst rating of Buy, based on 34 analysts covering the stock. Of those, 18 recommend buying, 15 recommend holding, and 1 recommend selling.
The analyst consensus price target for BPMC is $141.00, representing a +8.9% upside from the current price of $129.46. Price targets range from a low of $132.00 to a high of $150.00.
